Impact Factor
3.90
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
5.12
885 total citations
h5-index
38
h5 depth signal
Cited share
83.2%
149 of 179
Total citations
885
Citation footprint
Metric signal
4.67
External metric anchor
Self-citation
1.5%
13 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
345
United Kingdom
115
Italy
88
Australia
69
Spain
50
Citing Fields of Research
Antibiotic & Antibacterial Agents
303
HIV
89
Virology
88
Bacteriology
83
Fungal Pathogenesis
76
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
3,744
Articles tracked across the journal lifetime
Indexed publication set
179
149 cited publications
Last 12 months
84
7.0 publications/month
Open access share
17.9%
15 OA publications in the last year
Leading citing country
United States
345 citing publications
Leading citing field
Antibiotic & Antibacterial Agents
303 citing publications
Latest tracked publication
12 October 2026
10 recent records available
Coverage & Indexing History
v2n1, Feb. 1989,v14n1, Feb. 2001-
v2n1,Feb. 1989,v14n1, Feb. 2001-
Active Coverage
Research Focus & Classification
Indexed Subjects
Antibiotic & Antibacterial Agents
Fungal Pathogenesis
Virology
HIV
Viral Identification & Phylogenetics
Sexually Transmitted Diseases
Broad Categories
Communicable Diseases
Antibiotic & Antibacterial Agents
Viral Identification & Phylogenetics
Virology
HIV
Parasitology
MeSH Descriptors
Communicable Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/qco.0000000000001242
Open DOI
Reducing antibiotic burden in gram-negative bacteraemia: duration optimization and early oral transition
Purpose of review: Gram-negative bloodstream infections have traditionally been managed with prolonged and intravenous antibiotic therapy. This review aims to summarize the evidence supporting strategies to reduce antibiotic burden throu...
02
DOI 10.1097/qco.0000000000001253
Open DOI
Clinical and genetic risk factors for apolipoprotein L1-mediated chronic kidney disease in people of African ancestry with HIV
Purpose of review: To summarize current understanding of the epidemiology, pathogenesis and management of HIV-Associated Nephropathy (HIVAN) and other forms of Apolipoprotein L1 (APOL1)-mediated chronic kidney disease (CKD) in people of ...
03
DOI 10.1097/qco.0000000000001248
Open DOI
Screening for multidrug-resistant organism: clinical benefit or unquestioned routine
Purpose of review: Current strategies for multidrug-resistant organism (MDRO) screening are primarily intended to support infection prevention programs. However, accumulating evidence indicates that intestinal colonization also provides ...
04
DOI 10.1097/qco.0000000000001249
Open DOI
Severe strongyloidiasis and Gram-negative bacterial superinfections: epidemiology, clinical implications, and therapeutic strategies
Purpose of review: Strongyloidiasis is a neglected tropical disease affecting over 600 million people worldwide. Its severe forms carry a fatality rate exceeding 60%, yet death is rarely attributable to the parasite alone: the terminal e...
05
DOI 10.1097/qco.0000000000001238
Open DOI
Managing KPC infections in daily practice: when BLBLIs are interchangeable – and when they are not
Purpose of review: Κlebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales infections are currently treatable with novel β-lactam-β-lactamase inhibitors (BLBLIs) combinations, but their optimal use in daily practice requires...
06
DOI 10.1097/qco.0000000000001245
Open DOI
Adenovirus infection after cellular therapy: diagnostic and therapeutic challenges
Purpose of review: To review recent advances in the epidemiology, diagnosis, and management of human adenovirus (HAdV) infection following haematopoietic cell transplantation (HCT) and other cellular therapies, with emphasis on risk stra...
07
DOI 10.1097/qco.0000000000001244
Open DOI
Endemic Mycoses in 2026: can we keep the pace of redrawing maps?
Purpose of review: The dimorphic fungal infections were classically grouped as endemic mycoses due to their restricted geographic distribution. However, their original geographic distribution dates from the twentieth century and true pre...
08
DOI 10.1097/qco.0000000000001241
Open DOI
Fungal diseases in burn and blast-injured patients: tensions are rising, and awareness must keep pace
Purpose of review: Invasive fungal diseases (IFD) are severe complications of burn injury and are associated with substantial morbidity and mortality. Despite increasing recognition of their clinical impact, evidence guiding diagnosis, p...
09
DOI 10.1097/qco.0000000000001240
Open DOI
Machine learning to differentiate colonization from infection in multidrug-resistant Gram-negative bacteria: implications for further research
Purpose of review: Machine learning has emerged as a promising tool to support antimicrobial decision-making in infectious diseases. In colonized patients, distinguishing multidrug-resistant Gram-negative bacteria (MDR-GNB) colonization ...
10
DOI 10.1097/qco.0000000000001237
Open DOI
Using bacteriophage cocktails in MDR Gram-negative infections: a practical manual
Purpose of review: Bacteriophage therapy is a promising treatment on the horizon for multidrug resistant (MDR) and difficult-to-treat infections. Recent findings: There have been a number of case reports and case series using bacteriopha...
Bibliographical & Catalog Notes
Also issued online.